Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Verastem ( (VSTM) ) just unveiled an announcement.
Verastem, Inc. has appointed Matthew E. Ros as Chief Operating Officer effective January 14, 2025. Mr. Ros brings over 35 years of experience in global pharmaceutical and biotechnology sectors, previously serving in leadership roles at FORE Biotherapeutics and Epizyme, Inc. In this new role, he will receive a base salary of $485,000 with eligibility for a performance-based bonus, and stock units contingent upon his continued service and achievement of specific milestones. This strategic appointment is expected to strengthen Verastem’s operational capabilities and strategic direction, potentially impacting stakeholder interests positively.
More about Verastem
YTD Price Performance: -17.87%
Average Trading Volume: 1,467,055
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $237.2M
For detailed information about VSTM stock, go to TipRanks’ Stock Analysis page.
